Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios?

Catafau AM, Bullich S, Seibyl JP, Barthel H, Ghetti B, Leverenz J, Ironside JW, Schulz-Schaeffer WJ, Hoffmann A, Sabri O.

J Nucl Med. 2016 Nov;57(11):1740-1745.

PMID:
27363836
2.

Clinical and imaging characteristics of late onset mitochondrial membrane protein-associated neurodegeneration (MPAN).

Gore E, Appleby BS, Cohen ML, DeBrosse SD, Leverenz JB, Miller BL, Siedlak SL, Zhu X, Lerner AJ.

Neurocase. 2016 Oct;22(5):476-483.

PMID:
27801611
3.

Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort.

Pillai JA, Butler RS, Bonner-Jackson A, Leverenz JB.

Dement Geriatr Cogn Disord. 2016;42(1-2):106-16. doi: 10.1159/000448243.

PMID:
27623397
4.

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease.

Davis MY, Johnson CO, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Quinn JF, Chung KA, Peterson-Hiller AL, Rosenthal LS, Dawson TM, Albert MS, Goldman JG, Stebbins GT, Bernard B, Wszolek ZK, Ross OA, Dickson DW, Eidelberg D, Mattis PJ, Niethammer M, Yearout D, Hu SC, Cholerton BA, Smith M, Mata IF, Montine TJ, Edwards KL, Zabetian CP.

JAMA Neurol. 2016 Oct 1;73(10):1217-1224. doi: 10.1001/jamaneurol.2016.2245.

PMID:
27571329
5.

Arguing against the proposed definition changes of PD.

Boeve BF, Dickson DW, Duda JE, Ferman TJ, Galasko DR, Galvin JE, Goldman JG, Growdon JH, Hurtig HI, Kaufer DI, Kantarci K, Leverenz JB, Lippa CF, Lopez OL, McKeith IG, Singleton AB, Taylor A, Tsuang D, Weintraub D, Zabetian CP.

Mov Disord. 2016 Nov;31(11):1619-1622. doi: 10.1002/mds.26721. Review.

PMID:
27492190
6.

Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings.

Crane PK, Gibbons LE, Dams-O'Connor K, Trittschuh E, Leverenz JB, Keene CD, Sonnen J, Montine TJ, Bennett DA, Leurgans S, Schneider JA, Larson EB.

JAMA Neurol. 2016 Sep 1;73(9):1062-9. doi: 10.1001/jamaneurol.2016.1948.

PMID:
27400367
7.

Retinal Nerve Fiber Layer Thinning in Alzheimer's Disease: A Case-Control Study in Comparison to Normal Aging, Parkinson's Disease, and Non-Alzheimer's Dementia.

Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, Jones SE, Ehlers JP, Leverenz JB.

Am J Alzheimers Dis Other Demen. 2016 Aug;31(5):430-6. doi: 10.1177/1533317515628053.

PMID:
26888864
8.

Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study.

Seibyl J, Catafau AM, Barthel H, Ishii K, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Takao M, Akatsu H, Murayama S, Bullich S, Mueller A, Koglin N, Schulz-Schaeffer WJ, Hoffmann A, Sabbagh MN, Stephens AW, Sabri O.

J Nucl Med. 2016 Jun;57(6):900-6. doi: 10.2967/jnumed.115.161927.

PMID:
26823561
9.

Associations between Markers of Glucose and Insulin Function and Cognitive Function in Healthy African American Elders.

Skinner JS, Morgan A, Hernandez-Saucedo H, Hansen A, Corbett S, Arbuckle M, Leverenz JB, Wilkins CH, Craft S, Baker LD.

J Gerontol Geriatr Res. 2015 Aug;4(4). pii: 232.

10.

Response to the letter "Haptoglobin phenotype and Parkinson disease risk" by Delanghe et al.

Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H.

Parkinsonism Relat Disord. 2016 Jan;22:110-1. doi: 10.1016/j.parkreldis.2015.10.021. No abstract available.

PMID:
26708126
11.

The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease.

Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP.

Mol Neurodegener. 2015 Sep 24;10:50. doi: 10.1186/s13024-015-0045-4.

12.

GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Mata IF, Leverenz JB, Weintraub D, Trojanowski JQ, Chen-Plotkin A, Van Deerlin VM, Ritz B, Rausch R, Factor SA, Wood-Siverio C, Quinn JF, Chung KA, Peterson-Hiller AL, Goldman JG, Stebbins GT, Bernard B, Espay AJ, Revilla FJ, Devoto J, Rosenthal LS, Dawson TM, Albert MS, Tsuang D, Huston H, Yearout D, Hu SC, Cholerton BA, Montine TJ, Edwards KL, Zabetian CP.

Mov Disord. 2016 Jan;31(1):95-102. doi: 10.1002/mds.26359.

PMID:
26296077
13.

A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease.

Mischley LK, Leverenz JB, Lau RC, Polissar NL, Neradilek MB, Samii A, Standish LJ.

Mov Disord. 2015 Oct;30(12):1696-701. doi: 10.1002/mds.26351.

14.

Haptoglobin phenotype modifies serum iron levels and the effect of smoking on Parkinson disease risk.

Costa-Mallen P, Zabetian CP, Agarwal P, Hu SC, Yearout D, Samii A, Leverenz JB, Roberts JW, Checkoway H.

Parkinsonism Relat Disord. 2015 Sep;21(9):1087-92. doi: 10.1016/j.parkreldis.2015.07.006.

15.

Group comparison of spatiotemporal dynamics of intrinsic networks in Parkinson's disease.

Madhyastha TM, Askren MK, Zhang J, Leverenz JB, Montine TJ, Grabowski TJ.

Brain. 2015 Sep;138(Pt 9):2672-86. doi: 10.1093/brain/awv189.

16.

R47H Variant of TREM2 Associated With Alzheimer Disease in a Large Late-Onset Family: Clinical, Genetic, and Neuropathological Study.

Korvatska O, Leverenz JB, Jayadev S, McMillan P, Kurtz I, Guo X, Rumbaugh M, Matsushita M, Girirajan S, Dorschner MO, Kiianitsa K, Yu CE, Brkanac Z, Garden GA, Raskind WH, Bird TD.

JAMA Neurol. 2015 Aug;72(8):920-7. doi: 10.1001/jamaneurol.2015.0979.

17.

High copy wildtype human 1N4R tau expression promotes early pathological tauopathy accompanied by cognitive deficits without progressive neurofibrillary degeneration.

Wheeler JM, McMillan PJ, Hawk M, Iba M, Robinson L, Xu GJ, Dombroski BA, Jeong D, Dichter MA, Juul H, Loomis E, Raskind M, Leverenz JB, Trojanowski JQ, Lee VM, Schellenberg GD, Kraemer BC.

Acta Neuropathol Commun. 2015 Jun 4;3:33. doi: 10.1186/s40478-015-0210-6.

18.

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ; Florbetaben Phase 3 Study Group..

Alzheimers Dement. 2015 Aug;11(8):964-74. doi: 10.1016/j.jalz.2015.02.004.

19.

A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

Cornejo-Olivas MR, Torres L, Mata IF, Mazzetti P, Rivas D, Cosentino C, Inca-Martinez M, Cuba JM, Zabetian CP, Leverenz JB.

Parkinsonism Relat Disord. 2015 May;21(5):444-8. doi: 10.1016/j.parkreldis.2015.01.005.

20.

Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease.

Bekris LM, Tsuang DW, Peskind ER, Yu CE, Montine TJ, Zhang J, Zabetian CP, Leverenz JB.

Mov Disord. 2015 Jun;30(7):936-44. doi: 10.1002/mds.26172.

Items per page

Supplemental Content

Loading ...
Support Center